EE461 Cost-Effectiveness of Nivolumab as an Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma at High Risk of Recurrence With Tumor Cell Pd-L1 Expression ≥ 1% in Denmark
作者
F Kamgar,SH Thybo,Kasper Munk Johannesen,S Teitsson,TH Brodtkorb
出处
期刊:Value in Health [Elsevier BV] 日期:2022-12-01卷期号:25 (12): S146-S146